http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CY-1111659-T1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eedb53b18972fa06716e56945d4388ed |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-323 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39583 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
filingDate | 2010-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d86dda3493b00bf6e8055eb8a289451 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd2a591c74f4129d1a06b7ef4ce4f602 |
publicationDate | 2015-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CY-1111659-T1 |
titleOfInvention | METHOD OF EVALUATION OF RISK OF ISchemic Cardiovascular Disease Using Phosphorylcholine Conjugates |
abstract | Levels of IgG and IgM autoantibodies against phosphorylcholine in subjects with hypertension (diastolic pressure> 95 mmHg) at baseline were determined to determine the importance of antibodies for the development of atherosclerosis. The results indicate that the increase in IMT at four years post-baseline was significantly less pronounced in subjects with high autoantibodies, particularly IgM autoantibodies, to phosphorylcholine. Therefore the presence or absence of autoantibodies, in particular IgM autoantibodies, to phosphorylcholine is associated with an increased or decreased risk of developing ischemic cardiovascular disease. The present invention proposes a method for the determination of antibodies, particularly phosphorylcholine IgM antibodies, for the identification of individuals at risk for developing ischemic cardiovascular disease. Animal experiments indicate that moderate to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a hemocyanin bladder (KLH) -phosphorylcholine conjugate. A pharmaceutical composition comprising a phosphorylcholine conjugate (active immunization) or an antibody preparation, for example a monoclonal antibody, selectively to a phosphorylcholine conjugate (passive immunization) and the use of such compositions as active or passive immunogens is proposed. of atherosclerosis. |
priorityDate | 2004-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Predicate | Subject |
---|---|
isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483782 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1014 |
Total number of triples: 30.